China's Pharmaceutical Industry To Government Regulation

Pharmaceutical industries in the countries around the world have been implementing strict government regulation. Most developed countries have implemented social regulation on pharmaceutical industries, not only to ensure the product safe and effective, protect the interests of public health and life, but also improve market information on the non-pharmaceutical symmetric state, and encourage and facilitate the innovation incentives of the pharmaceutical industry. Through the visible hand of government and the invisible hand of market mechanism, the developed countries not only get out of the counterfeit drugs flooding the market, but also become the world-based pharmaceutical company, and have accounted for an important map of the world pharmaceutical market. Compared with developed countries, the time of Chinese government on the pharmaceutical industry regulation is short and lack of experience. As the prosperity of China's pharmaceutical market, there also are some serious hidden dangers, such as the irrational structure of the pharmaceutical market, which make it difficult to upgrade and optimize the industrial structure. The low innovation capability of pharmaceutical companies makes it unable to participate in international preparations market. The diseconomies scale of China's pharmaceutical lead to lower profitability and losses. This is because the traditional view of pharmaceutical industry regulation is mostly along a single idea of social regulation, which is work well in developed countries. However, in the transition period our country, government regulation of pharmaceutical industry is not only social regulation, it may not be able to achieve our goal on industrial development. Therefore, this article explores the dual regulatory system of government regulation, not only strengthen the social regulation, but also strengthen the economic regulation. The economic regutlaiton includes the access regulation and price regulation, and promote the pharmaceutical industry to the Pareto efficiency of resource allocation.In this paper, we use the government regulation of China's pharmaceutical industry as key discussion and use methods of normative analysis, comparative analysis, and general to specific iedas, static to dynamic ideas, systematic and comprehensive analysis. This paper can bee is divided into eight parts. The first chapter is the introduction. In ths part we introduce the research background, research significance, research object and methods, research ideas and research framework, as well as papers innovations. Chapter II is the literature review of government regulation. In this part, firstly, we have conducted literature review of domestic and foreign government regulation; secondly, we have conducted literature review of domestic and foreign government regulation on pharmaceutical industry; thirdly, we give some comments on the related literature. Chapter III is the theoretical research framework of government regulation on pharmaceutical industry. In the part, we firstly clarify the concept, characteristics and attributes of the pharmaceutical industry; secondly, we have explore the demand and supply of government regulation on pharmaceutical industry; thirdly, we analyze the objective and content of government regulation on pharmaceutical industry; at last, we explore the cost-benefit performance of government regulation on pharmaceutical industry. Chapter IV is background of government regulation whcich based on the analysis of SCP. In the part, we use of the structure - conduct - performance (SCP) paradigm to analyze the status of China's pharmaceutical industry, and has laid a background to government regulation. Chapter V is the comparison between China's government regulation on pharmaceutical industry and developed countries's government regulation on pharmaceutical industry, which includes the entry regulation, price regulation, information regulation and quality regulation. Chapter VI is the dynamics history of China's pharmaceutical industry and the problems of China's government regulation on pharmaceutical industry. Chapter VII is the countermeasure of China's government regulation on pharmaceutical industry, and includes the social regulation, economic regulation and the supporting reform. Chapter VIII is the conclusions of this research and research prospects, summarizes the main conclusions of this article, and future research directions.